Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocytepredominant Hodgkin lymphoma: A report from the German Hodgkin Study Group

Blood

Volumn 118, Issue 16, 2011, Pages 4363-4365

  Eichenauer, Dennis A ^a   Fuchs, Michael ^a   Pluetschow, Annette ^a   Klimm, Beate ^a   Halbsguth, Teresa ^a   Böll, Boris ^a   Von Tresckow, Bastian ^a   Nogova, Lucia ^a   Borchmann, Peter ^a   Engert, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; RITUXIMAB; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; LYMPHADENECTOMY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; UNSPECIFIED SIDE EFFECT;

EID: 80054835220     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-06-361055     Document Type: Article

References (10)

1. Engert A, Eichenauer DA, Dreyling M. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl 5):168-171.
2. Nogova L, Reineke T, Brillant C, et al. Lymphocyte- predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol. 2008; 26(3):434-439. (Pubitemid 351171696)
3. Anagnostopoulos I, Hansmann ML, Franssila K, et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood. 2000;96(5):1889-1899. (Pubitemid 30661074)
4. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008;111(1):109-111.
5. Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003; 101(11):4285-4289. (Pubitemid 36857790)
6. Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol. 1999;17(3):776-783. (Pubitemid 29109305)
7. Mauz-Korholz C, Gorde-Grosjean S, Hasenclever D, et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma: experience from the European Network Group on Pediatric Hodgkin Lymphoma. Cancer. 2007;110(1):179-185. (Pubitemid 46986431)
8. Al-Mansour M, Connors JM, Gascoyne RD, Skinnider B, Savage KJ. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol. 2010;28(5):793-799.
9. Nogova L, Reineke T, Eich HT, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol. 2005; 16(10):1683-1687. (Pubitemid 41510144)
10. Chen RC, Chin MS, NgAK, et al. Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol. 2010;28(1):136-141.